-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239

Benzinga·11/03/2026 16:16:22
Listen to the news
UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $256 to $239.